Trilogy International Partners Inc., together with its subsidiaries, provides wireless voice and data communications services to customers and international visitors roaming on its networks in the United States, Bolivia, and New Zealand. Its wireless voice and data communications services include local, international long distance, and roaming services. The Company also provides fixed broadband communications services to business and residential customers. It serves approximately 15.4 million customers. The company is headquartered in Bellevue, Washington.
Industry, Sector and Symbol
Stock Exchange TSE
Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
SymbolTSE:TRL
CUSIPN/A
Phone+1-425-4585900
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-2.92%
Return on EquityN/A
Return on Assets-2.98%
Miscellaneous
EmployeesN/A
Outstanding Shares55,276,000
Market CapC$305.41
Trilogy International Partners (TSE:TRL) Frequently Asked Questions
What is Trilogy International Partners' stock symbol?
Trilogy International Partners trades on the Toronto Stock Exchange (TSX) under the ticker symbol "TRL."
How often does Trilogy International Partners pay dividends? What is the dividend yield for Trilogy International Partners?
Trilogy International Partners declared a quarterly dividend on Friday, April 13th. Shareholders of record on Friday, May 4th will be paid a dividend of 0.02 per share on Friday, May 4th. This represents a $0.08 dividend on an annualized basis and a yield of 1.90%. The ex-dividend date is Friday, April 13th. View Trilogy International Partners' Dividend History.
What price target have analysts set for TRL?
3 brokers have issued 12 month target prices for Trilogy International Partners' shares. Their predictions range from C$5.50 to C$8.00. On average, they anticipate Trilogy International Partners' share price to reach C$7.17 in the next year. This suggests a possible upside of 70.6% from the stock's current price. View Analyst Ratings for Trilogy International Partners.
What is the consensus analysts' recommendation for Trilogy International Partners?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trilogy International Partners in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Who are some of Trilogy International Partners' key competitors?
Some companies that are related to Trilogy International Partners include Mayne Pharma Group (MYX), Vectura Group (VEC), Eco Animal Health Group (EAH), Allergy Therapeutics (AGY), Sinclair Pharma (SPH), Pharmaxis (PXS), NanoViricides (NNVC), Futura Medical (FUM), Cathay International (CTI), Sareum (SAR), N4 Pharma (N4P), China Pharma (CPHI) and Bayer (BAYN).
Who are Trilogy International Partners' key executives?
Trilogy International Partners' management team includes the folowing people:
- Mr. John William Stanton, Co-Founder & Chairman (Age 63)
- Mr. Bradley Jay Horwitz, Pres, CEO & Non-Independent Director (Age 62)
- Ms. Theresa E. Gillespie, Co-Founder & Non-Independent Director (Age 65)
- Mr. Erik Mickels, Sr. VP & CFO
- Ms. Ann Saxton, VP, Investor Relations & Corp. Devel.
Has Trilogy International Partners been receiving favorable news coverage?
Headlines about TRL stock have been trending somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Trilogy International Partners earned a media sentiment score of 0.05 on Accern's scale. They also assigned news headlines about the specialty pharmaceutical company an impact score of 45.47 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
How do I buy shares of Trilogy International Partners?
Shares of TRL and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Trilogy International Partners' stock price today?
One share of TRL stock can currently be purchased for approximately C$4.20.
How big of a company is Trilogy International Partners?
Trilogy International Partners has a market capitalization of C$305.41 million.
How can I contact Trilogy International Partners?
Trilogy International Partners' mailing address is Bellevue Wa PO Box 1988, BELLEVUE, WA 98009-1988, United States. The specialty pharmaceutical company can be reached via phone at +1-425-4585900.
MarketBeat Community Rating for Trilogy International Partners (TSE TRL)
MarketBeat's community ratings are surveys of what our community members think about Trilogy International Partners and other stocks. Vote "Outperform" if you believe TRL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRL will underperform the S&P 500 over the long term. You may vote once every thirty days.
